ESMO Breast 2020 | SAFIR02-IMMUNO: PDL1 copy number changes predicts checkpoint blockade inhibitor efficacy in mBC

Name: SAFIR02-IMMUNO: PDL1 copy number changes predicts checkpoint blockade inhibitor efficacy in mBC
Uploaded: 2020-05-22T00:00:00Z
Duration: 6 min 46 s
Description: Thomas Bachelot, MD, PhD, of Centre Léon Bérard, Lyon, France, discusses a subgroup analyses of the SAFIR02-IMMUNO study (NCT02299999) which aimed to determine the efficacy of genome analysis as a therapeutic decision tool for patients with metastatic breast cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Thomas Bachelot • 22 May 2020

ESMO Breast 2020

Breast Cancer Antibodies Durvalumab

SAFIR02-IMMUNO

Thomas Bachelot, MD, PhD, of Centre Léon Bérard, Lyon, France, discusses a subgroup analyses of the SAFIR02-IMMUNO study (NCT02299999) which aimed to determine the efficacy of genome analysis as a therapeutic decision tool for patients with metastatic breast cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).